Results 111 to 120 of about 1,472,051 (229)

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

open access: yesMolecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu   +12 more
wiley   +1 more source

Landscape of BRAF transcript variants in human cancer

open access: yesMolecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda   +5 more
wiley   +1 more source

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

open access: yesMolecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song   +11 more
wiley   +1 more source

Breakthrough Solution for Antimicrobial Resistance Detection: Surface‐Enhanced Raman Spectroscopy‐based on Artificial Intelligence

open access: yesAdvanced Materials Interfaces, EarlyView., 2023
This review discusses the use of Surface‐Enhanced Raman Spectroscopy (SERS) combined with Artificial Intelligence (AI) for detecting antimicrobial resistance (AMR). Various SERS studies used with AI techniques, including machine learning and deep learning, are analyzed for their advantages and limitations.
Zakarya Al‐Shaebi   +4 more
wiley   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

open access: yesMolecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton   +17 more
wiley   +1 more source

Mapping-based genome size estimation. [PDF]

open access: yesBMC Genomics
Natarajan S, Gehrke J, Pucker B.
europepmc   +1 more source

Karyotype and genome size variation in Delphinium subg. Anthriscifolium (Ranunculaceae). [PDF]

open access: yesPhytoKeys, 2023
Luo XY   +6 more
europepmc   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

open access: yesMolecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald   +18 more
wiley   +1 more source

Karyotype and genome size analyses for two spiders of the lycosidae family. [PDF]

open access: yesFront Genet
Zhang Y   +10 more
europepmc   +1 more source

Genome size and intron size in Drosophila [PDF]

open access: yesMolecular Biology and Evolution, 1998
Dmitri A. Petrov   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy